Why have ovarian cancer mortality rates declined? Part III. Prospects for the future (Q38530989)

3 September 2017

1 reference

title

Why have ovarian cancer mortality rates declined? Part III. Prospects for the future (English)

1 reference

3 September 2017

1 reference

4

Steven A Narod

1 reference

3 September 2017

Victoria Sopik

1

1 reference

3 September 2017

Barry Rosen

series ordinal

2

1 reference

3 September 2017

Vasily Giannakeas

series ordinal

3

1 reference

3 September 2017

language of work or name

English

0 references

publication date

15 June 2015

1 reference

3 September 2017

1 reference

3 September 2017

volume

138

1 reference

3 September 2017

issue

3

1 reference

3 September 2017

page(s)

757-761

1 reference

Why have ovarian cancer mortality rates declined? Part I. Incidence

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Why have ovarian cancer mortality rates declined? Part II. Case-fatality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

A model for estimating ovarian cancer risk: application for preventive oophorectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Genetic/familial high-risk assessment: breast and ovarian, version 1.2014

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Germline RAD51C mutations confer susceptibility to ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Germline mutations in RAD51D confer susceptibility to ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

PPM1D mutations in circulating white blood cells and the risk for ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Breast-cancer risk in families with mutations in PALB2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Mutations in BRIP1 confer high risk of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Preventing ovarian cancer through genetic testing: a population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Identification of six new susceptibility loci for invasive epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Population distribution of lifetime risk of ovarian cancer in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

ACOG Practice Bulletin No. 89. Elective and risk-reducing salpingo-oophorectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

The fallopian tube: primary site of most pelvic high-grade serous carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Ovarian cancer risk after salpingectomy: a nationwide population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Salpingectomy to prevent ovarian cancer: A Countercurrents Series

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Effect of Screening on Ovarian Cancer Mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Potential markers that complement expression of CA125 in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

A novel approach to predict the likelihood of specific ovarian tumor pathology based on serum CA-125: a multicenter observational study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

A framework for a personalized surgical approach to ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.019

10.1016/J.YGYNO.2015.06.019

7 January 2021

Identifiers

DOI

1 reference

3 September 2017

1 reference